Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web
C.R. Bard, Inc. · Decision date Jul 15, 2026
What did the FDA decide?
FDA records P800002/S035 as a supplement to PMA P800002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 15, 2026.
FDA approval order statement
updated water system equipment for the Woburn, MA manufacturing site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jul 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P800002/S035
- Regulatory pathway
- PMA supplement
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Jul 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P800002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P800002 · Original PMA
AVITENE MICROFIBRILLAR COLLAGEN HEMOSTAT NON-WOVEN WEB
P800002/S035 received
Application receipt date recorded by FDA.
P800002/S035 · FDA decision
30-Day Notice
P800002/S036 · Related supplement
Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web Webber
Timeline entries are records held by MedtechLedger for P800002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P800002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA approval | Oct 24, 1980 | FDA | |
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Davol Inc., Sub. C. R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S081 | Ferrosan Meidcal Devices A/S | PMA supplement | Jun 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
C.R. Bard, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 160 New Boston St., Woburn, MA, 01801
Sources and methodology
- Original FDA record: P800002/S035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

